Stock Monitor: XTL Biopharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on RXi Pharmaceuticals Corp. (NASDAQ: RXII), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On December 11, 2017, the Marlborough, Massachusetts-based Company announced a research collaboration with Medigene AG to explore potential synergies of using RXi's self-delivering RNAi technology (sd-rxRNA®) in combination with Medigene's recombinant TCRs, to develop modified T cells with enhanced efficacy. Sign up now for our free research reports at:
Active-Investors.com is currently working on the research report for XTL Biopharmaceuticals Ltd (NASDAQ: XTLB), which also belongs to the Healthcare sector as the Company RXi Pharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, RXi Pharma most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:
The preclinical research program will examine the applicability of RXi's sd-rxRNA technology to be integrated into Medigene's process to produce receptor-modified T cells.
Results Could Create Powerful Cell Therapies Against Serious Cancers
Commenting on the collaboration, Dr. Geert Cauwenbergh, President and CEO of RXi Pharma, stated that Medigene's adoptive cell therapy, using their TCR platform, is a very attractive and promising development in immuno-oncology. Dr. Geert added that the use of RXi's immuno-oncology sd-rxRNA compounds with Medigene's receptor-modified T cells could potentially create a next generation of very powerful adoptive cell therapies against serious cancers that currently are difficult to target.
RXi's Important Collaboration Agreements of 2017
On December 01, 2017, RXi and the Center for Cancer Immune Therapy at Herlev Hospital, entered into a collaborative research agreement to evaluate the potential of RXi's novel self-delivering RNAi (sd-rxRNA®) technology platform in TILs for the use in treatment for a number of cancer types, including melanoma and ovarian cancer.
RXi and Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, signed a collaborative research agreement to evaluate the potential of RXi's sd-rxRNA technology platform for use in cancer treatments. The agreement was announced on November 2017.
On May 22, 2017, PCI Biotech, a cancer focused biopharmaceutical company, and RXi announced that the extension of their preclinical research collaboration initiated in 2015. The preclinical research collaboration evaluated technology compatibility and synergy based on in vivo studies.
Medigene's TCRs Technology
The TCR technology aims at arming the patient's own T cells with tumor-specific T-cell receptors. The receptor-modified T cells are then able to detect and efficiently kill tumor cells. This immunotherapy approach attempts to overcome the patient's tolerance towards cancer cells and tumor-induced immunosuppression by activating and modifying the patient's T cells outside the body. TCR therapy is developed to utilize a higher number of potential tumor antigens than other T cell-based immunotherapies.
Medigene's TCR pipeline is being built to contain a collection of TCRs that recognize different antigens which are expressed by various types of tumor. The Company's proprietary TCR platform technology for the identification and selection of natural TCRs is protected by exclusively in-licensed patents in Europe, the US, and Japan.
About Medigene AG
Established in 1994 and headquartered in Munich, Germany, Medigene AG is a publicly listed biotechnology company developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company concentrates on the development of personalized T cell-based immunotherapies.
About RXi Pharmaceuticals Corp.
Founded in 2011, RXi Pharma is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. RXi developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to a broad spectrum of therapeutic areas.
Stock Performance Snapshot
December 12, 2017 - At Tuesday's closing bell, RXi Pharma's stock fell 1.61%, ending the trading session at $0.64.
Volume traded for the day: 262.15 thousand shares.
Stock performance in the last month – up 18.65%; previous three-month period – up 21.23%; past six-month period – up 3.63%
After yesterday's close, RXi Pharma's market cap was at $15.21 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.3% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.